Examples of Neotope Biosciences in a sentence
Prothena's business consists of a substantial portion of Elan's former drug discovery business platform, including Neotope Biosciences Limited and its wholly owned subsidiaries Onclave Therapeutics Limited and Prothena Biosciences Inc (which for the period prior to separation and distribution are collectively referred to herein as the “Prothena Business”).
Each “significant subsidiary” of the Company (as such term is defined in Rule 1-02 of Regulation S-X, which, for the avoidance of doubt, shall include Prothena Biosciences Limited (formerly Neotope Biosciences Limited), Neotope Neuroscience Limited, Othair Prothena Limited, Prothena Biosciences Inc.
The Parent Company subsequently made a capital contribution of $103.5 million to Neotope Biosciences Limited.
Cost: At 1 January 2011 1,634.7 Share-based compensation 33.4 Other (97.5 ) At 1 January 2012 1,570.6 Addition 18.2 Capital contribution to Neotope Biosciences Limited 103.5 Distribution to Prothena Corporation, plc.
Prothena's business consists of a substantial portion of Elan's former drug discovery business platform, including Neotope Biosciences Limited and its wholly owned subsidiaries Onclave Therapeutics Limited and Prothena Biosciences Inc (which for the period prior to separation and distribution are referred to herein as the “Prothena Business”).
Neotope Biosciences also has a program focused on the potential treatment of type 2-diabetes.
With a copy to: Neotope Biosciences, a division of Elan Pharmaceuticals, Inc.
The Parent Company divested of its shareholding in Neotope Biosciences Limited in December 2012 as part of the demerger of the wholly-owned subsidiaries comprising the Prothena Business to Prothena, in exchange for Prothena issuing Prothena ordinary shares directly to Elan shareholders, on a pro rata basis.
Martin commented further, “By establishing Neotope Biosciences and Elan as distinct businesses – each with its own specific business characteristics and dynamics - we provide investors with important clarity, transparency and choice as it relates to their investment decisions.” Mr. Martin added, “For Elan Corporation, plc, the completion of this transaction is a natural progression and final step to becoming a company that generates both profits and growth to the benefit of stakeholders.
Neotope Master Process Development and Clinical Supply Agreement / Appendix 2B-2 confidential Appendix 2B-2: [***] Project Plan — [***] [***] Neotope Biosciences Limited (“Neotope”), Elan Pharma International Limited (“EPIL”) and Boehringer Ingelheim Pharma GmbH & Co. KG (“BI Pharma”) entered into a Master Process Development and Clinical Supply Agreement effective June 23, 2010 (the “Original MSA”).